US4483853A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Amino acid isomers, their production and their medicinal use
Assignee: Individual
•
Filing: 1982-10-14
•
Granted: 1984-11-20
•
Expires: 2002-10-14
Abstract
Abstract The (-)-D-isomers of compounds of the general formula ##STR1## in which X stands for an acidic radical, especially a radical of phosphonic acid, sulphonic acid, boronic acid or tetrazole, R stands for an alkylene, alkenylene or alkynylene radical with 3 or more carbon atoms, preferably 3 to 6 carbon atoms, or a C 3 to C 7 cycloalkyl radical, and A and B independently of each other stand for a hydrogen atom or a lipophilic radical, especially an ester radical, or salts thereof, or pharmaceutically acceptable bioprecursors thereof, especially (-)-D-aminophosphonopentanoic acid and (-)-D-aminophosphonoheptanoic acid, find use in the treatment of diseases of the central nervous system. The compound aminophosphonoheptanoic acid is also novel as a racemic mixture and the present invention also relates to that compound in racemic form which may be used in the same way as the said (-)-D-isomers.
Inventors
- 👤 James F. Collins
- 👤 Kenneth Curry
- 👤 Robert Schwarcz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 20:23
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/3804; C07F9/3808; A; A61; A61P; A61P25/00; A61P25/08; C07F9/40; C07F9/4003; C07F9/4006
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
46 words
A method of combatting a disease of the central nervous system in a human and non-human animal which comprises administering to the animal the (-)-D-isomer of aminophosphonoheptanoic acid or an ester or a salt thereof, or a pharmaceutically acceptable bioprecursor thereof effective to combat the disease.
Claim 2
Independent Claim
46 words
A method of combatting a disease of the central nervous system in a human and non-human animal which comprises administering to the animal the (-)-D-isomer of aminophosphonoheptanoic acid or an ester or a salt thereof, or a pharmaceutically acceptable bioprecursor thereof effective to combat the disease.
Claim 3
Dependent Claim
16 words
A method according to claim 1 in which the active compound is administered by intracerebral injection.
Claim 4
Dependent Claim
19 words
A method according to claim 1, wherein there is administered, (-)-D-aminophosphonoheptanoic acid, or a racemic mixture of aminophosphonoheptanoic acid.
Claim 5
Dependent Claim
15 words
A method according to claim 1 wherein the compound is free of the (+) isomer.
Claim 6
Dependent Claim
12 words
A method according to claim 4 wherein there is administered (-)-D-aminophosphonoheptanoic acid.
Claim 7
Dependent Claim
19 words
A method according to claim 1 wherein there is administered (-)-D-aminophosphonoheptanoic acid, a salt thereof or an ester thereof.
Claim 8
Dependent Claim
15 words
A method according to claim 6 wherein the compound is free of the (+) isomer.
Claim 9
Dependent Claim
12 words
A method according to claim 1 wherein there is administered (D)-aminophosphonoheptanoic acid.
Claim 10
Independent Claim
47 words
A method of blocking ibotenic acid-excited receptors comprising administering to a vertebrate mammal an amount of the (-)-D isomer of aminophosphonoheptanoic acid or an ester of a salt thereof, or a pharmaceutically acceptable bioprecursor thereof effective to block ibotenic acid-excited receptors but not block kainic acid-excited receptors.
Claim 11
Independent Claim
47 words
A method of blocking ibotenic acid-excited receptors comprising administering to a vertebrate mammal an amount of the (-)-D isomer of aminophosphonoheptanoic acid or an ester of a salt thereof, or a pharmaceutically acceptable bioprecursor thereof effective to block ibotenic acid-excited receptors but not block kainic acid-excited receptors.
Claim 12
Dependent Claim
15 words
A method according to claim 9 wherein the compound is free of the (+) isomer.
Claim 13
Dependent Claim
19 words
A method according to claim 9 wherein there is administered (-)-D-aminophosphonoheptanoic acid, a salt thereof or an ester thereof.
Claim 14
Dependent Claim
15 words
A method according to claim 11 wherein the compound is free of the (+) isomer.
Claim 15
Dependent Claim
12 words
A method according to claim 11 wherein there is administered (-D)-aminophosphonoheptanoic acid.
Claim 16
Dependent Claim
15 words
A method according to claim 13 wherein the compound is free of the (+) isomer.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-11-20 | 1988-05-21 | 1988-11-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-11-20 | 1992-05-21 | 1992-11-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-11-20 | 1996-05-21 | 1996-11-20 | $7700.00 | Window Closed / Lapsed |